BioLineRxNASDAQ: BLRX

- Steady growth in APHEXDA ®  adoption in first full quarter post-approval - - Among top 80 transplant centers, secured APHEXDA formulary placement to date at institutions representing ~26% of stem cell transplant procedures performed - on track to reach stated goal of ~35% by end of Q2 - - Announced new data in abstract accepted at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting on pilot phase of ongoing Phase 2b pancreatic cancer clinical trial collaboration with Columbia University  - - Collaboration partner Gloria Biosciences' motixafortide HSC mobilization bridging study IND was filed and approved by the Center for Drug Evaluation of the National Medical Products Administration in China. Anticipate clinical trial initiation 2H 2024 - - Completed debt and equity financing totaling $26 million to support U.S. commercialization of APHEXDA and advance lifecycle expansion activities  - - Management to host conference call today, May 28, at 8:30 am EDT - TEL AVIV, Israel , May 28, 2024 /PRNewswire/ -- BioLineRx Ltd.

BioLineRx Ltd., a biopharmaceutical company focusing on oncology and rare diseases, has received a notification letter from Nasdaq.

In almost every situation, investors should stay away from penny stocks. They're extremely speculative and they tend to facilitate delusions of grandeur.

BioLineRx gains approval for a blood cancer drug that aids in stem cell transplantation. Motixafortide, the flagship drug, shows promising results in mobilizing blood stem cells and in combination with other treatments for pancreatic cancer. Financially, BioLineRx has a limited amount of cash on hand but has secured a licensing deal that provides additional funds.

BioLineRx is a biopharmaceutical company specializing in cancer and rare disease therapies. The company's main product, Aphexda, was FDA-approved for stem cell mobilization in multiple myeloma patients. BioLineRx's low cash reserves and need for additional financing pose risks, but its valuation appears relatively conservative.

BioLineRx Ltd. (NASDAQ:BLRX ) Q3 2023 Earnings Conference Call November 20, 2023 10:00 PM ET Company Participants John Lacey - Head of IR & Corporate Communications Phil Serlin - CEO Holly May - President of BioLineRx USA Mali Zeevi - CFO Conference Call Participants Joe Pantginis - H.C.

In general, penny stock investing is all about quick gains. Investors in this high-risk world usually are in it for a quick buck.

BioLineRx has received approval for their stem cell mobilizing compound, motixafortide, for certain forms of blood cancer. The compound has shown impressive results in mobilizing stem cells in patients, with a high success rate in optimal stem cell collection. However, there are concerns about competition from generic versions of a similar drug and the decreasing need for immediate autologous transplants in patients with multiple myeloma.

Bioline RX Ltd (NASDAQ:BLRX) shares jumped at the market open on Monday after the US Food and Drug Administration approved the use of Aphexda (motixafortide) in combination with filgrastim for patients with multiple myeloma, a type of bone marrow cancer. The company's Nasdaq-listed shares rose as much as 23% in pre-market trading before opening 10% higher at $2.33.